A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules
A PHASE 2b, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MenABCWY ADMINISTERED ON 2 DIFFERENT DOSING SCHEDULES IN HEALTHY PARTICIPANTS ≥11 TO <15 YEARS OF AGE
Sponsor: Pfizer
Listed as NCT04440176, this observational or N/A phase trial focuses on Meningococcal Vaccine and remains completed. Sponsored by Pfizer, it has been updated 16 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
16 versions recorded-
Apr 28, 2026 — Present [daily]
Completed
Phase: PHASE2 → None
-
Feb 2025 — Apr 2026 [monthly]
Completed PHASE2
-
Sep 2024 — Feb 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 11 earlier versions
-
Sep 2022 — Mar 2024 [monthly]
Active Not Recruiting PHASE2
-
Mar 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE2
-
Feb 2022 — Mar 2022 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Dec 2021 — Feb 2022 [monthly]
Recruiting PHASE2
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE2
-
Sep 2021 — Nov 2021 [monthly]
Recruiting PHASE2
-
Feb 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Sep 2020 — Oct 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2020 — Sep 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Jun 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
This study is designed to describe the short-term immunogenicity and safety of 2 doses of Neisseria meningitidis group A, B, C, W, and Y vaccine (MenABCWY) separated by either 12 or 36 months during adolescence, and immunopersistence up to 24 months after completing 2 doses separated by a 12-month interval.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .